ocriplasmin (Jetrea, ThromboGenics)

Research offers insights to success in macular hole surgery
Research offers insights to success in macular hole surgeryMacular hole surgery can be performed using various techniques and technologies. According to John T. Thompson, MD, the available evidence supports always incorporating internal limiting membrane (ILM) peeling, staining of the ILM, and having a large gas bubble in the eye on the first postoperative day.
Findings reaffirm ocriplasmin success for symptomatic VMA over long termResults of a 2-year phase IIIb study include findings consistent with earlier information about treatment success with ocriplasmin injection for symptomatic vitreomacular adhesion and new information about efficacy and safety over the longer term.
‘Real-world’ ocriplasmin macular hole closure rates lag trialsOcriplasmin (Jetrea, ThromboGenics) may achieve lower macular hole closure rates than in trials, new British and Irish data suggests. Also, “the incidence of adverse events was greater than previously reported,” wrote RJ Haynes of Bristol Eye Hospital in Bristol, United Kingdom, and colleagues in the journal Eye.
OASIS study shows positive results for ocriplasmin injectionAnalyses of data from the OASIS study confirm the efficacy of intravitreal ocriplasmin for the treatment of symptomatic vitreomacular traction/vitreomacular adhesion (VMT/VMA) and the importance of proper patient selection, said Peter K. Kaiser, MD.
Ocriplasmin promising in real-world vitreomacular traction trialVitreomacular traction resolved in one-third of patients treated with ocriplasmin (Jetrea, ThromboGenics) within 28 days in a phase IV study of the new medication, according to Dr David Steel.
Patients report positive results from ocriplasmin for vitreomacular adhesionImprovement in patients’ assessment of visual function was reported after treatment with intravitreal ocriplasmin for vitreomacular adhesion.
Patient criteria vital to VMA success
Patient criteria vital to VMA successPostmarketing clinical experience with ocriplasmin shows treatment success is higher when patients are chosen based on ideal criteria. No safety signals have emerged, but safety is being investigated more closely in ongoing trials.
Ocriplasmin for VMA: Lessons learnedAnalyses of data from patients treated for vitreomacular adhesion at a single center provide insights for management decisions and patient counseling.